BioNTech Brings ADC Breakthrough and Restructuring Plan to ASCO as Cancer Pipeline Takes Center Stage

BioNTech enters one of its most consequential weeks since the pandemic, armed with a $19.6 billion cash pile, a $1 billion share buyback, and a sweeping cost-cutting programme that will eliminate nearly 1,860 jobs. The transformation from a COVID-19 vaccine manufacturer into a commercial-stage oncology player hinges on data being unveiled at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, which runs until 2 June.

The spotlight falls squarely on the antibody-drug conjugate (ADC) Trastuzumab Pamirtecan. In a Phase 2 cohort of 145 patients with HER2-positive advanced endometrial cancer, the candidate delivered a confirmed objective response rate of 47.9% and a median progression-free survival of 8.1 months. The US Food and Drug Administration granted both Fast Track and Breakthrough Therapy designations in 2023, and BioNTech, together with partner DualityBio, plans to file a Biologics License Application next year, subject to regulatory feedback. In China, the National Medical Products Administration has already accepted the application for review.

Two other pipeline hopefuls are also making presentations. On 30 May, BioNTech is scheduled to give oral updates on Pumitamig and Gotistobart. Pumitamig, a PD-L1/VEGF bispecific antibody, is being tested in the Phase 2/3 ROSETTA Lung-02 trial as a first-line therapy for non-small cell lung cancer, combined with chemotherapy. For Gotistobart, a PD-1 inhibitor, the company is releasing overall survival data in patients with platinum-resistant ovarian cancer who have been previously treated. The results were not yet available at the time of publication.

Analyst sentiment ahead of the conference is mixed but leans bullish. Canaccord Genuity reaffirmed its Buy recommendation on 28 May, albeit with a reduced price target of $158, down from $171 earlier in the month. Wells Fargo followed suit on 22 May, also keeping a Buy rating. In contrast, Bernstein SocGen initiated coverage on 22 May with a Market Perform rating and a $96 price target, citing uncertainty in the clinical development plan for Pumitamig and the wider drug class. The broader consensus, drawn from 19 analysts polled by S&P Global, is a Buy with an average target of $122.60, though estimates range from $75.55 to $156.38 — a sign of how heavily the valuation depends on pipeline execution.

Should investors sell immediately? Or is it worth buying BioNTech?

Financially, BioNTech is well positioned to weather the transition. First-quarter 2026 revenue came in at €118.1 million, with a net loss of €531.9 million. For the full year, the company has guided for revenue of €2.0 billion to €2.3 billion, equivalent to $2.3 billion to $2.6 billion. The balance sheet holds €16.8 billion (roughly $19.6 billion) in cash and equivalents, and management has authorized a $1 billion share repurchase programme to run over the next twelve months.

The restructuring is equally ambitious. Production sites in Idar-Oberstein, Marburg, Singapore and at partner CureVac are being closed or downsized, affecting around 1,860 employees. Annual savings of approximately $585 million are expected by 2029, with the freed-up capital redirected toward building oncology commercialisation capabilities.

The clinical pipeline remains the ultimate driver. BioNTech now runs more than 25 Phase 2 and Phase 3 trials, including 13 registrational studies. For Pumitamig alone, five new pivotal trials have recently been launched — targeting triple-negative breast cancer, microsatellite-stable colorectal cancer, gastric cancer and two non-small cell lung cancer settings. Further interim Phase 3 data are expected later this year.

BioNTech at a turning point? This analysis reveals what investors need to know now.

Shares closed on Friday at €82.30 in Frankfurt, up roughly 4% on the week but still 19% below the 52-week high of €101.90 set on 3 June 2025. The stock has barely budged year-to-date, down 0.24%, and has lost 5.4% over the past month. With a 30-day annualised volatility of 31%, Monday’s open could swing sharply depending on how the oncology readouts are received.

Whatever the near-term reaction, the ASCO data represent a critical inflection point. A successful BLA filing would mark BioNTech’s first oncology approval and make the post-COVID pivot tangible — a milestone that the company’s $19.6 billion war chest and aggressive cost discipline have been designed to support.

Ad

BioNTech Stock: New Analysis - 30 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69446116 |